ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved..
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Cell reports - 39(2022), 5 vom: 03. Mai, Seite 110757 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seow, Jeffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.05.2022 Date Revised 06.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2022.110757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340059680 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340059680 | ||
| 003 | DE-627 | ||
| 005 | 20240306232114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2022.110757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM340059680 | ||
| 035 | |a (NLM)35477023 | ||
| 035 | |a (PII)S2211-1247(22)00521-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seow, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.05.2022 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a neutralization breadth | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a variant of concern | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a Graham, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Hallett, Sadie R |e verfasserin |4 aut | |
| 700 | 1 | |a Lechmere, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Maguire, Thomas J A |e verfasserin |4 aut | |
| 700 | 1 | |a Huettner, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Hataf |e verfasserin |4 aut | |
| 700 | 1 | |a Pickering, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Rebekah |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Anele |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Christopher C |e verfasserin |4 aut | |
| 700 | 1 | |a Mant, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Pitcher, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Malim, Michael H |e verfasserin |4 aut | |
| 700 | 1 | |a Doores, Katie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 39(2022), 5 vom: 03. Mai, Seite 110757 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:5 |g day:03 |g month:05 |g pages:110757 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2022.110757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 5 |b 03 |c 05 |h 110757 | ||